CD38 and plasma cell myeloma: The discovery that the ectoenzyme CD38 was highly expressed on the cell surface plasma cells led to one of the most significant therapeutic advancements in myeloma of the past decade – the advent of anti-CD38 targeting antibodies (97, 98).